Oxycodone in Personal Injury Claims
Managing oxycodone use in CTP and personal injury claims. What you need to assess, red flags, and pathways to safer pain management.
Published: 3 April 2026 | Updated: 3 April 2026
What is Oxycodone?
Oxycodone is a strong opioid painkiller derived from opium. It works by binding to opioid receptors in the brain and spinal cord, dampening pain signals and creating a sense of well-being. It's available in immediate-release tablets (for acute pain) and extended-release formulations (for chronic pain). You'll often see it marketed as Oxycontin (extended-release) or as generic immediate-release tablets.
Oxycodone is appropriate for moderate to severe pain, particularly pain from cancer, significant injury, or post-surgery recovery. However, it carries substantial risks: addiction potential, tolerance (requiring escalating doses), respiratory depression, constipation, and falls in older patients. In personal injury and CTP claims, oxycodone is frequently prescribed in the acute phase, but its long-term use warrants careful scrutiny.
Oxycodone in Personal Injury and CTP Claims: The Patterns
Oxycodone appears in personal injury claims for acute pain immediately post-injury and sometimes extends into chronic pain management. In workers compensation claims, acute musculoskeletal injuries often involve short-term oxycodone; more complex injuries with persistent pain may justify longer-term use. CTP claims (motor vehicle accidents) frequently involve oxycodone in the weeks and months following injury.
The problem: many claimants remain on oxycodone months or years after the acute phase, often at doses escalated beyond what's evidence-based, with limited documentation of clinical justification or attempts to reduce use. This pattern reflects both prescriber inertia and genuine complexity in some cases; your job is to distinguish legitimate use from inappropriate continuation.
Oxycodone Doses in Claims
Typical doses in claims vary widely. Immediate-release tablets usually start at 5-10 mg per dose, three times daily. Extended-release formulations begin at 10-20 mg daily and may be escalated to manage pain. However, evidence suggests that doses above 120 mg daily are associated with minimal additional pain relief and significantly higher risks. Many claimants in your portfolio are likely prescribed doses well above what evidence supports, particularly after the acute injury phase.
Risk Assessment: When Should You Refer for Review?
Step 1: Check the Timeline
Is the claimant still on oxycodone months after acute injury? This is a red flag. While some claimants do need longer-term opioid management, most should be weaning down by 3-6 months post-injury. If use persists beyond this without documented clinical justification or evidence of structured pain management, refer for review.
Step 2: Assess the Dose
Doses above 100 mg daily are high-risk in the chronic setting. Doses escalating rapidly (increasing by 10-20 mg per month) suggest either inadequate pain control or concerning prescribing patterns. Either way, this warrants pharmacist assessment.
Step 3: Check for Concurrent Sedatives
Is the claimant also prescribed benzodiazepines (like diazepam) or other sedatives? This combination dramatically increases overdose risk. Immediate review is warranted if oxycodone and benzodiazepines are prescribed concurrently.
Step 4: Review Other Measures
Is the claimant in physiotherapy, receiving psychological support, or involved in pain management programs? If oxycodone is the only pain management strategy, particularly long-term, the claim lacks a robust pain management plan. Your pharmacist should assess whether additional interventions would reduce opioid need.
Red Flags in Oxycodone Claims
- Oxycodone prescribed acutely, then continued indefinitely without periodic reassessment or tapering plan.
- Rapid dose escalation without documented clinical justification.
- Oxycodone combined with benzodiazepines or other CNS depressants.
- Prescriber lacks specialisation in pain management; doses seem unusually high for the documented injury.
- No documented attempts to reduce oxycodone or transition to safer alternatives despite years of use.
- Concurrent multiple opioids (e.g., oxycodone plus tramadol plus codeine-containing analgesics).
- Claimant reports adverse effects (sedation, constipation, falls) but oxycodone continues at the same dose.
- Pain levels documented as unchanged or worsening despite escalating doses.
Transitioning from Oxycodone: Your Role
If your claimant is on long-term oxycodone, your insurer should work toward gradual reduction as recovery progresses. This isn't about abrupt cessation (which is unsafe) but about planned, structured tapering supported by allied health interventions. Your pharmacist should recommend:
- Gradual dose reduction (typically 5-10 percent every 1-2 weeks, adjusted for patient tolerance).
- Concurrent uptake in physiotherapy, occupational therapy, or pain psychology to manage pain without escalating opioids.
- Consideration of non-opioid alternatives: paracetamol, NSAIDs (if appropriate), nerve pain agents like pregabalin or gabapentin, and topical agents.
- Support for comorbid depression or anxiety, which often drives perceived need for higher doses.
- Regular monitoring with clear milestones: "Reduce oxycodone by 5 mg every two weeks; if pain worsens, pause tapering and review additional pain strategies."
The Evidence Base
Long-term oxycodone use for non-cancer pain is increasingly questioned in clinical guidelines. Recent research from Australia, New Zealand, and overseas suggests that persistent high-dose opioid use is associated with poorer pain outcomes, higher disability, increased overdose risk, and no meaningful improvement in quality of life compared with multimodal pain management. Most clinical guidelines now recommend against high-dose opioids in chronic non-cancer pain, particularly beyond 6-12 months.
For claimants managing chronic pain from old injuries, structured tapering with concurrent pain management interventions typically leads to lower pain levels and better functional outcomes than staying on high-dose oxycodone. This is not punitive; it's evidence-based practice.
Safety Monitoring: What Questions to Ask Your Pharmacist
- Is oxycodone use still clinically justified given the time since injury and documented pain levels?
- Is the current dose evidence-based for the documented indication?
- What is the rationale for any recent dose escalations?
- Are there adverse effects (constipation, sedation, falls, impaired cognition) that should trigger dose reduction?
- What non-opioid and non-pharmacological pain management strategies are in place?
- Is there a structured tapering plan if oxycodone continues long-term?
- Are there comorbidities (depression, anxiety, sleep apnea) that should be addressed to reduce opioid dependency?
- Is the claimant monitored for signs of dependence or diversion (doctor shopping, early requests for repeats)?
Summary: Your Decision Framework
Oxycodone is appropriate in personal injury and CTP claims for acute pain in the weeks and months post-injury. However, long-term use requires strong clinical justification, active monitoring, and a clear pathway toward reduction as recovery progresses. If your claimant is on oxycodone months or years post-injury without documented attempts to reduce it, without adequate non-opioid pain management, or at doses above 100 mg daily, refer for a medication review. Your pharmacist can assess whether continued oxycodone is justified or whether safer pain management approaches would lead to better outcomes.
Managing long-term oxycodone in your claims?
IMM's pharmacists review opioid prescribing in personal injury and CTP claims, assessing whether long-term use is justified, identifying tapering opportunities, and recommending safer pain management alternatives. We work with your claims team to support evidence-based transitions that improve claimant outcomes.
Request a Medication Review
